FILE:ALXN/ALXN-8K-20050817135735.txt.gz
EVENTS:	Other Events	Financial Statements and Exhibits
TEXT:
ITEM: Other Events
ITEM: Financial Statements and Exhibits
 
 
 
 
 
 
 
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( General Instruction A.2. below):
see
 
 
 
 
 
ITEM 8.01. OTHER EVENTS.
 
On August 17, 2005, Alexion Pharmaceuticals, Inc. issued a press release announcing the completion of its public offering of 2,500,000 shares of common stock. A copy of that press release is filed as Exhibit 99.1 to this Report.
 
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
 
(c) Exhibits
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 

Exhibit 99.1
 
 
 
 
 Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) announced today that it completed its previously announced public offering of 2,500,000 shares of its common stock. The gross proceeds, before discounts, commissions and expenses, of the offering are approximately $66,875,000. Alexion intends to use the proceeds from this offering for general corporate purposes.
CHESHIRE, Conn., August 17, 2005
 
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities. A shelf registration statement relating to the shares of common stock has previously been filed with and declared effective by the Securities and Exchange Commission. This offering of shares of common stock was made only by means of a prospectus supplement and accompanying prospectus. Morgan Stanley & Co. Incorporated acted as underwriter for the offering. Copies of the prospectus supplement and the accompanying prospectus may be obtained from Morgan Stanley, attention Prospectus Delivery Department: 1585 Broadway, New York, New York 10036-8200, (212) 761-6775.
 


